YUYU PHARMA, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4,635 KRW | -1.28% |
|
+0.98% | -12.22% |
| Sales 2022 | 139B 101M 8.41B | Sales 2023 | 137B 99.75M 8.31B | Capitalization | 85.44B 62.12M 5.18B |
|---|---|---|---|---|---|
| Net income 2022 | -5.99B -4.35M -363M | Net income 2023 | -7.18B -5.22M -435M | EV / Sales 2022 | 0.8 x |
| Net Debt 2022 | 8.5B 6.18M 515M | Net Debt 2023 | 7.05B 5.13M 427M | EV / Sales 2023 | 0.67 x |
| P/E ratio 2022 |
-16.4
x | P/E ratio 2023 |
-11.9
x | Employees | 318 |
| Yield 2022 |
1.69% | Yield 2023 |
-
| Free-Float | 52.39% |
More Fundamentals
* Assessed data
More news
| 1 day | -1.28% | ||
| 1 week | +0.98% | ||
| Current month | -8.58% | ||
| 1 month | -10.69% | ||
| 3 months | -9.47% | ||
| 6 months | +3.46% | ||
| Current year | -12.22% |
1 week
4 570.00
4 780.00
1 month
4 500.005 250.00
Current year
4 500.006 730.00
1 year
4 160.007 440.00
3 years
4 160.0012 200.00
5 years
3 460.0018 950.00
10 years
3 415.0018 950.00
| Managers | Title | Age | Since |
|---|---|---|---|
Won-Sang Yu
CEO | Chief Executive Officer | 50 | 06/20/06 |
Seong-Wook Baek
PRN | Corporate Officer/Principal | 65 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Won-Sang Yu
CEO | Chief Executive Officer | 50 | 06/20/06 |
Seung-Ahn Gang
BRD | Director/Board Member | 83 | - |
Hyung-Moon Ahn
BRD | Director/Board Member | 43 | 31/17/31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 4,635 | -1.28% | 40,263 |
| 25/24/25 | 4,695 | -0.53% | 14,624 |
| 24/24/24 | 4,720 | +0.53% | 30,964 |
| 23/24/23 | 4,695 | -0.11% | 28,319 |
| 22/24/22 | 4,700 | +2.40% | 31,967 |
End-of-day quote Korea S.E., April 26, 2024
More quotes
Yuyu Pharma, Inc. is a Korea-based company engaged in the provision of pharmaceutical products. The Company produces prescription drugs such as circulatory improvement agents, antiplatelet agents, osteoporosis drugs, antiulcerants, bone metabolism ameliorants, gout preparative drugs, antidepressants, anti-diabetic agents, antitubercular agents, antihypertensive agents, angina pectoris drugs, antibiotics, hemorrhoidal and varicose preparations, topical corticosteroids and others, as well as non-prescription drugs such as vitamins and digestive agents. It also provides healthcare supplements and quasi drugs. In addition, the Company is involved in the provision of medicines for geriatric diseases such as osteoporosis, dementia, stroke and others.
Sector
Pharmaceuticals
Calendar
13/05/2024
- Q1 2024 Earnings Release (Projected)
Chiffre d''affaires - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -12.22% | 54.48M | |
| +5.31% | 70.44B | |
| +10.97% | 8.94B | |
| -16.83% | 4.75B | |
| +43.48% | 4.5B | |
| +3.20% | 3.85B | |
| -21.36% | 2.34B | |
| -29.67% | 2.2B | |
| +8.38% | 1.96B | |
| +3.90% | 1.65B |
- Stock Market
- Equities
- A000220 Stock
